NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BLEEDnFIRE Therapeutics

BLEEDnFIRE Therapeutics

Private
BernHealthcare & Life Scienceshttps://bleednfire-tx.com/

Last Round

Grant

May 27, 2026

Total Funding Raised

$170,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BLEEDnFIRE Therapeutics is a biotechnology company developing first-in-class RNA-based therapies for rare bleeding disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

RNA therapeuticssiRNArare bleeding disordersbiotech startupRNAi platformcoagulation therapyGalNAc-conjugatedProtein Shemophilia treatmentdrug developmentsubcutaneous dosingRNA medicinepreclinical biotechrare disease drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BLEEDnFIRE Therapeutics Comps

Public and private peers based on sector, stage, and business model.

BLEEDnFIRE Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

BLEEDnFIRE Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 27, 2026
GrantNov 29, 2024

BLEEDnFIRE Therapeutics Investors

Notable investors and investment history

BLEEDnFIRE Therapeutics investors
InvestorRounds
Gebert Rüf StiftungGrant
KickfundGrant
InnosuisseGrant
Venture KickGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2026

    Received funding from Kickfund, Gebert Rüf Stiftung, Innosuisse, and Venture Kick.

BLEEDnFIRE Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BLEEDnFIRE Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BLEEDnFIRE Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBern
Year Founded2025
Last FundingMay 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.